Nevro (NYSE: NVRO) is a public multinational medical technology company headquartered in Redwood City, California. We have developed HF10™ therapy, an innovative, evidence-based neuromodulation platform.
We started with a simple mission to help more patients suffering from chronic pain. At each stage of development, our research was subject to the highest levels of scientific rigor, resulting in a new therapy that has impacted the lives of over 36,000 patients around the world.
The Nevro® Senza® SCS System received CE mark in 2010, TGA approval in 2011, FDA approval in 2015, and is commercially available in Europe, Australia, and the United States.
The Vice President of Investor Relations (VP of IR) is a critical leadership role which manages the strategic planning, ongoing development, and coordination of all investor relations activities to enhance Nevro’s impact among our stakeholders, including the investment and analyst communities. This person is responsible for broadening and increasing shareholder value through effective communication and engagement, and acts as a corporate spokesperson representing the organization.
The VP of IR reports to the CFO and has significant interaction with the Executive, Commercial, Clinical, R&D and Legal & Finance teams and must demonstrate clear ability to communicate and work effectively in a team environment.